

PRESS RELEASE

03 April 2023 09:57:00 CEST

TetraGraph enables significant cost savings according to data presented at annual pediatric meeting in the US

The abstract "A Quality Improvement Project to Reduce Sugammadex Cost and Waste by Using Aliquots and Quantitative Neuromuscular Monitoring" presented at the annual SPA-AAP meeting in Texas, US, shows cost savings from reduced dosage of reversal medication for neuromuscular blocking agents when using TetraGraph

Uppsala, Sweden, April 3, 2023. Senzime AB (publ) today announced that data presented at annual meeting hosted by the Society for Pediatric Anesthesia (SPA) and the American Academy of Pediatrics (AAP) shows significant savings from reduced dosing of Sugammadex, a medication for the reversal of neuromuscular blockade, when monitoring patients undergoing procedures with TetraGraph. TetraGraph is Senzime's quantitative neuromuscular monitor based on electromyography (EMG).

"At our institution approximately 8,000 patients per year receive neuromuscular blocking drugs and reversal, and we see possible annual net savings of USD 370,000 using an EMG-monitor as TetraGraph", said Mark Twite, Professor of Anesthesiology at the University of Colorado & MD at Children's Hospital Colorado. "The reduction of Sugammadex medication usage also resulted in less waste, decreasing the environmental impact."

The study was conducted between October 10 to December 9, 2022, at Children's Hospital Colorado (CHC), and included 203 procedures in the analysis. The age and weight of the patients ranges from 1 month to 36 years and 3 to 138 kg. As much as 20 percent, i.e., 41 patients out of 203, did not require any Sugammadex because a train-of four ratio equal to, or more than, 90% was achieved spontaneously as measured by quantitative EMG monitoring using TetraGraph. The reduction in use of Sugammadex implies significant cost savings.

"TetraGraph is primarily for improving patient safety and reducing complications, but it is important to see data that shows that we not only improve patient safety but also save costs for the hospitals", said Pia Renaudin, CEO of Senzime.

About TetraGraph®

TetraGraph is a quantitative neuromuscular monitor, based on the gold standard electromyography (EMG) technology which provides accurate and versatile monitoring of neuromuscular blockade. The product is designed to meet the needs of monitoring physiological data during surgery of patients receiving general anesthesia and muscle relaxation using muscle paralyzing drugs. TetraGraph stimulates the patient's peripheral nerve using the TetraSens® disposable sensors and measures, analyzes, and displays the muscle's potential in real time. Thanks to its small size and versatile features, TetraGraph can be used in any type of surgery, anywhere in the hospital environment, and can be connected to external monitors and electronic hospital records.

For further information, please contact:

Pia Renaudin, CEO of Senszime AB

Phone: +46 (0) 708 13 34 17, e-mail: pia.renaudin@senzime.com

Paula Treutiger, Head of Communication and IR

Phone: +46 (0) 733 66 65 99, e-mail: paula.treutiger@senzime.com

About Senszime

Senzime is a Swedish medical device company that develops, manufactures, and markets CE- and FDA-cleared patient monitoring systems. Senszime's employees worldwide are committed to the vision of a world without anesthesia- and respiratory-related complications. The company markets an innovative portfolio of solutions, including the TetraGraph® and ExSpirom® 2Xi for real-time monitoring of neuromuscular and respiratory functions, typically under and after surgery. The goal is to help eliminate in-hospital complications, and radically reduce health care costs related to surgical and high acuity procedures.

Senzime targets a market opportunity valued more than SEK 40 billion per year, and operates with sales teams in the world's leading markets. The company's shares are listed on Nasdaq Stockholm Main Market (SEZI). More information is available at senzime.com.

Attachments

[TetraGraph enables significant cost savings according to data presented at annual pediatric meeting in the US](#)